Human Papillomavirus Vaccine: For Boys, Too?

Jenson, Hal
March 2007
Travel Medicine Advisor;Mar2007, Vol. 17 Issue 3, p15
The article discusses an immunogenicity study of the quadrivalent human papillomavirus vaccine (HPV). The vaccine was studied for immunogenicity and reactogenicity in boys and girls aged 10-15 and 16-23 years. The study confirms the higher immunogenicity among younger vaccines, including boys. Mathematical modeling of HPV vaccination designs showed that a female-only vaccination policy will likely be 35-40% less effective in preventing cervical cancer than vaccination of both genders.


Related Articles

  • Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix™]: Profile Report. Keam, Susan J; Harper, Diane M // BioDrugs;2008, Vol. 22 Issue 3, p205 

    The article focuses on the vaccines for Human Papillomavirus (HPV) types 16 and 18. It informs that a prophylactic vaccine against oncogenic HPV types is likely to be of value as a prevention strategy. It is stated that for long-term effect, a cervical cancer vaccine needs to lead to a strong...

  • Genotypes of the human papillomavirus: Relevance to Indian field trials of the vaccine. Hariharan, Indhu; Pillai, M. Radhakrishna // Indian Journal of Medical Research;Sep2009, Vol. 130 Issue 3, p247 

    Highly effective HPV vaccines are likely to become available for use in India shortly. The availability and validation of the vaccines to prevent oncogenic HPV infection associated lesions from progressing to cancer has clearly offered a cost effective long-term strategy to reduce the cervical...

  • HPV vaccination ± screening could be valuable in India.  // PharmacoEconomics & Outcomes News;9/6/2008, Issue 561, p6 

    The article discusses a study which suggests that human papillomavirus (HPV) vaccination at a cost of < 10 international dollars per girl could be very cost-effective, and combining this with screening could be even more effective and still cost-effective. It references a study by M. Diaz et al....

  • Human papillomavirus (HPV) vaccination: the impact on practice. Riley, Cate // Primary Health Care;Nov2008, Vol. 18 Issue 9, p41 

    The article discusses on the impact of human papillomavirus (HPV) vaccination on medical practice in Great Britain. Research reveals that the introduction into the HPV vaccine's national immunisation schedule will affect the workload of school nurses and practitioners working in primary care. It...

  • Vacuna contra el virus del papiloma humano. Juárez-Albarrán, Alfredo César; Juárez-Gámez, Carlos Alberto // Revista Medica del IMSS;nov/dic2008, Vol. 46 Issue 6, p631 

    Genital human papilloma virus infection (HPV) is the most common sexually transmitted infection worldwide, it is the cause of genital warts, and it is related with cervical cancer, the second most common cause of death from cancer in women in America, and the first in underdeveloped countries,...

  • HPV vaccine promises to fight cervical cancer. Perry, Leah // Drug Topics;3/20/2006, Vol. 150 Issue 6, p20 

    The article introduces a new vaccine that could eliminate the human papillomavirus (HPV), thereby aiding in fighting cervical cancer. During clinical trials of GlaxoSmithKline PLC's vaccine named Cervarix in November 2005, the drug had prevented 90 percent of new infections and all persistent...

  • Vaccines for Papillomavirus (HPV) Infection. Rodríguez-Cerdeira, C.; Alba, A. // Open Dermatology Journal;2009, Vol. 3, p129 

    Prophylactic HPV vaccination of both quadrivalent and bivalent vaccines has already been approved in Spain and is gaining popularity among Spanish women. Other European countries show similar trends. With the use of vaccines against HPV, especially the tetravalent vaccine, in the short or...

  • Response. Suba, Eric J.; Raab, Stephen S. // JNCI: Journal of the National Cancer Institute;8/21/2013, Vol. 105 Issue 16, p1254 

    A letter to the editor is presented in response to the article "Population-Level Impact of the Bivalent, Quadrivalent, and Candidate Nonavalent Human Papillomavirus Vaccines: A Comparative Model-Based Analysis" by E. J. Suba and colleagues in the 2013 issue.

  • Attitudes about human papillomavirus vaccine in young women. Kahn, Jessica A.; Rosenthal, Susan L.; Hamann, Tara; Bernstein, David I. // International Journal of STD & AIDS;May2003, Vol. 14 Issue 5, p300 

    Human papillomavirus (HPV) vaccines are under investigation, but little is known about attitudes regarding vaccination. The aims of this study were to identify attitudes about and intention to receive an HPV vaccine in young women using a theory-based model. Young women (n=52, mean age 25 years,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics